PacBio's Revenue Surges in 2023, Driven by Revio and Onso
Generated by AI AgentMarcus Lee
Tuesday, Jan 14, 2025 9:05 am ET1min read
DNA--
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, has announced preliminary unaudited revenue for the fourth quarter and full year 2023, showcasing significant growth driven by the launch of the Revio system and Onso sequencer. The company's revenue for the fourth quarter of 2023 is expected to reach $58.4 million, representing a year-over-year increase of 113%, while full-year revenue is anticipated to be $200.5 million, up 56% from the previous year.
The Revio system, launched in 2023, has been a significant contributor to PacBio's growth. This scalable, accurate long-read sequencing platform has enabled researchers to sequence more samples with lower DNA input requirements and increased capacity, driving sample elasticity and attracting more customers to PacBio's platforms. The company shipped a record number of Revio systems in 2023, totaling 173 systems, and received orders from over 70 customers for its Kinnex RNA kits, enabling scalable, cost-effective full-length RNA sequencing on PacBio Revio and Sequel IIe systems.
PACB--
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, has announced preliminary unaudited revenue for the fourth quarter and full year 2023, showcasing significant growth driven by the launch of the Revio system and Onso sequencer. The company's revenue for the fourth quarter of 2023 is expected to reach $58.4 million, representing a year-over-year increase of 113%, while full-year revenue is anticipated to be $200.5 million, up 56% from the previous year.
The Revio system, launched in 2023, has been a significant contributor to PacBio's growth. This scalable, accurate long-read sequencing platform has enabled researchers to sequence more samples with lower DNA input requirements and increased capacity, driving sample elasticity and attracting more customers to PacBio's platforms. The company shipped a record number of Revio systems in 2023, totaling 173 systems, and received orders from over 70 customers for its Kinnex RNA kits, enabling scalable, cost-effective full-length RNA sequencing on PacBio Revio and Sequel IIe systems.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet